Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in May 2025

Last updated: May 2025 A list of 50 VC (Venture Capital) funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in May 2025

Investor	Life Science Switzerland investments
Zürcher Kantonal Bank	5
Eclosion SA	4
Foundation for Innovation and Technology (FIT)	4
BlueOcean Ventures	2
BioMedPartners	2
Verve Ventures	2
Fongit Seed Invest	2
Kinled Holding	2
Versant Ventures	2
Lichtsteiner Foundation	2
High-Tech Gruenderfonds	2
Omega Funds	2
FAST — by GETTYLAB	2
EQT Life Sciences	2
Sunstone Life Science Ventures	2
Rheingau Founders	2
SOSV	2
VINCI CAPITAL	2
Recipharm Venture Fund	1
Amboy Street Ventures	1
Heritage Capital	1
Medicxi	1
Rhia Ventures	1
RH Capital	1
Founderful	1
JFG Life Sciences Foundation	1
S2S Ventures	1
Indaco Venture Partners	1
Think.Health	1
Novartis Venture Fund	1
HBM Healthcare Investments AG	1
Technology Fund	1
SICTIC	1
Primal Capital	1
Boehringer Ingelheim Venture Fund	1
Idinvest Partners	1
Esperante Ventures	1
Renaissance	1
White Loop Capital	1
Skyviews Life Science	1
Polytech Ventures	1
FiveT Capital AG	1
Horizon 2020	1
Kickfund	1
LongeVC	1
Kurma Partners	1
SR One	1
Privilège Ventures	1
Novo Holdings	1
Pivotal bioVenture Partners	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

DPhi Space — DPhi Space is a startup that specializes in shared satellites for hosted payloads to simplify access to space. The company's flagship product, Clustergate, is a modular platform that aggregates multiple payloads—such as sensors, antennas, or cameras—into a single container, allowing them to share a satellite. This approach reduces costs andcomplexity by optimizing satellite resources. Clustergate offers built-in in-orbit computing, AI processing, and real-time data analytics, enabling businesses to deploy and manage their technology in space without requiring specialized expertise.
Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

INERGIO — This EPFL spin-off is developing faster, portable energy units that offer ten times the power at half the weight of current technology. Founder Mahmoud Hadad’s fuel cell innovation, which uses standard butane or propane that’s safe and available worldwide, offers high autonomy. INERGIO’s fuel cell geometry allows unlimited scaling, making thetechnology suitable for applications ranging from charging consumer electronics to auxiliary power for drones to automobile fuel cells. The team has a working prototype and is looking to have its minimal viable product by summer 2020 to start the pilot project with potential partners and customers.
Brightank — Catalyzing your Decarbonization. Brightank accelerates decarbonization with ammonia cracking catalysts, turning ammonia into fuel for heavy transport, hydrogen supply, and power. EPFL spin-off
DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

Metafuels — Our breakthrough sustainable aviation fuel (SAF) technology, aerobrew™, will make affordable net-zero aviation a reality. The technology is innovative, highly scaleable and able to tap into future global renewable energy systems efficiently. Starting from renewable feedstocks including green hydrogen, driven by renewable electricity, andsustainably sourced CO2, for example from direct air capture, aerobrew™ provides an efficient route to large-scale production of e-kerosene, overcoming the scale up challenges and high costs of alternative e-fuels technologies. aerobrew™ is also compatible with the biogenic route whereby the carbon required for the process is derived from renewable and sustainable cellulosic biomass which, does not compete with the food chain (wood, miscanthus, etc.). With a high carbon conversion, high selectivity and a high overall SAF yield, aerobrew™ leads to attractive production economics and cost leadership. With a rapidly growing demand for SAF, aerobrew™ stands to contribute significantly to the decarbonisation of global aviation and to support the achievement of net zero 2050 targets.
Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
Orakl Oncology — Cultivated with love by the Orakl team.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

mo:re GmbH — Mo:re is building the new gold standard for organoid-based drug development by offering a lab platform that industrialises cell culture workflows.
Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
AICA SA — AICA believes programming robots should be at everyone's reach. We combine Artificial Intelligence & an intuitive interface, to help you relocate your production.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Alleviant Medical — Interventional therapy for congestive heart failure
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Backing engineers building awe, wonder, speed.

Investment focus

Software, Biotechnology, Health Care
Pre-Seed, Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Yakoa — Content creation is now AI-native. If your digital rights system isn't, it's holding you back. Discover our solutions.
Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.

Investment focus

Software, E-Commerce, Internet
Seed, Series A, Pre-Seed
Germany, United States, Poland

Portfolio highlights

MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
Akhetonics — Creating the first all-optical RISC Processor

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B, Funding Round
Switzerland, Germany

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

Recipharm Venture Fund is part of Recipharm AB.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round
Sweden, Switzerland

Portfolio highlights

NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.

Amboy Street Ventures focuses on sexual health and women’s health technology startups. Amboy Street Ventures was founded in 2021 and was headquartered in Los Angeles, USA.

Investment focus

Health Care, Women's, Biotechnology
Series A, Seed, Series B
United States, Sweden, Switzerland

Portfolio highlights

Alloy — Alloy is a telehealth company addressing the healthcare needs of women over 40.
Granata Bio — Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se

Heritage Bank

Investment focus

Biopharma, Life Science
Seed
Switzerland

Portfolio highlights

Lagosta — WHAT WE DO. At LAGOSTA, we take great care in sustainably farming the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs. Accelerated depletion of wild stocks due to overfishing and

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Ottimo Pharma — Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden.

Rhia Ventures invests in reproductive healthcare solutions that empower women.

Investment focus

Health Care, Biotechnology, Women's
Seed, Series A, Pre-Seed
United States, Canada, Israel

Portfolio highlights

Eli — Hormone testing redesigned so you can monitor anytime, anywhere.
Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
Twentyeight Health — Your birth control. Delivered to your door. Get a new or re-up existing prescriptions, free & fast deliveries and follow up messaging with doctors. $0 with insurance and starting at $16/pack without.

RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.

Investment focus

Health Care, Biotechnology, Health Diagnostics
Funding Round
United States

Portfolio highlights

Novocuff — Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.
Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
Seven Starling — Seven Starling offers comprehensive online care for postpartum mental health. Take the free assessment to get started.

Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.

Investment focus

Software, Artificial Intelligence, Information Technology
Pre-Seed, Seed, Series A
Switzerland, United Kingdom, Canada

Portfolio highlights

8links — Advanced Battery Tech at Scale with 8inks: Revolutionize cell design, manufacturing, and chemistry for TWh-level solutions .
EthonAI — The EthonAI Manufacturing Analytics System is a powerful software suite to achieve operational excellence at scale.
Anthropos — Anthropos is your career platform designed for individuals and companies to manage their careers at scale, inside and outside organizations.

JFG Life Sciences Foundation is a non-profit foundation.

Investment focus

Biopharma, Health Care, Biotechnology
Seed
Switzerland

Portfolio highlights

Invasight — Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
NXI Therapeutics — NXI Therapeutics - Creating Tomorrow's Immunotherapies | The beginning of a new era of specificity and safety in the immunosuppressive therapy market

Students run the whole VC operation and are supported by a strong network of mentors. S2S is organized as a cross-campus initiative (ETH Zurich, EPFL, HSG, UZH) that fosters collaboration between different existing entrepreneurial student organizations.

Investment focus

Health Care, Information Technology, Software
Pre-Seed, Funding Round, Convertible Note
Switzerland, Germany

Portfolio highlights

Rrreefs — Our mission is to regenerate degraded coral reefs at global scale - restoring rich marine biodiversity for a healthy ocean.
Yuon Control — Yuon Control offers an advanced and predictive heating control system designed to optimize heating networks. It makes an effective contribution to CO2 reduction.
Cotierra — Biochar made from agricultural residues in the tropics can become a gamechanger for farmers and climate change mitigation

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Italy, Switzerland, United States

Portfolio highlights

TES Pharma —
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
Valo Therapeutics — Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenovirusesinto targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, China

Portfolio highlights

Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases

Climate protection through innovative technologies. The Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions

Investment focus

Information Technology, Software, Biotechnology
Debt Financing, Grant, Seed
Switzerland

Portfolio highlights

FGen — FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.
Calopad — Calopad, awarded by the Swiss Confederation, offers a unique and the most holistic solution in pain therapy and muscle regeneration. The therapeutic deep heat of 42 degrees solves any muscle pain, muscle tension, or muscle spasms of chronic patients in the long term and in a highly efficient way through new forms of therapy. With the associatedapp, Calopad brings the physiotherapist digitally into any user's home and enables personalized all-around care in real time - utterly independent of time and place. In the future, the modular design will make it possible to combine different therapies such as heat, cold, or light with just one device, opening up the possibility of new therapeutic successes.
Selfrag — SELFRAG AG is specialized in the development of high voltage pulse power products, plants and systems for selective fragmentation of solid materials.

Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Nextesy — Nextesy is a pioneering start-up that uses AI to simplify and automate important business processes, allowing businesses to alleviate the strain of repetitive manual procedures while increasing operational efficiency and scalability.
Insurteam — Insurteam provides the benefits of its technology to all insurance companies that service the travel and leisure sector.

Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf

Investment focus

Software, Information Technology, Internet
Seed, Funding Round, Pre-Seed
Japan, Spain, Switzerland

Portfolio highlights

Hivello — Hivello is a Decentralized Physical Infrastructure Network aggregator. Contribute resources, connect with Web3 protocols, and effortlessly generate passive income.
RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

A corporate venture investment company focussed on investing in mid to late stage clinical stage therapeutics development companies in North America and Europe

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
United Kingdom, Switzerland, United States

Portfolio highlights

Amlo Biosciences — From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...
Acousia Therapeutics — Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss.Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells bycellular regeneration originating from supporting cells.ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity.
Spiral Therapeutics — Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic inDecember 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA.

Renaissance is an investment foundation for pension funds investing in Swiss SMEs. It acts as a partner of the SMEs, participating in companies within the framework of succession planning or company outsourcing and thus promotes the Swiss SME landscape by maintaining and creating jobs.The firm was founded in 1997 and is headquartered in Lausanne,Vaud.

Investment focus

Medical, Software, Health Care
Series B, Series C, Seed
Switzerland

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
GlassIG — It is an independent software vendor. Our aim is to provide market leading and cost effective Information Governance for everyone. At They are proud of our mission to serve and inspire our customers to establish and operate an effective Information Governance solution.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

White Loop Capital is the first investment firm specialized in crypto-assets in France. Accompanying those who dare.

Investment focus

Finance, Software, Life Science
Seed, Pre-Seed, Funding Round
Switzerland

Portfolio highlights

Ondefy — Ondefy is building infrastructure that enables a simple access to decentralized finance. Integrate multiple DeFi services unders 1 line of code.
Usual — Usual Labs operates as a decentralized finance(DeFi) protocol.
LayerZero Labs — LayerZero Labs is a blockchain messaging protocol developer that allows decentralized applications build across multiple blockchains. The company is a User Application (UA) configurable on-chain endpoint that runs a ULN.

Skyviews Life Science is a privately held advisory company specialised in personalised health.

Investment focus

Biotechnology, Food and Beverage, Medical
Series B, Series A, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

one.bio — BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States.
Volumina Medical — Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes.
Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — Relai is the easiest way to invest in Bitcoin for the long-term investor. A simple and intuitive app that allows users to buy and sell Bitcoin directly from their bank account within 1 minute, without registration, KYC verification or deposits. It was founded in 2019 and is headquartered in Zurich, Switzerland.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

FiveT is an independent alternative asset manager established in 2006. Starting in 2021, FiveT set out to finance the foundation of the hydrogen economy.

Investment focus

FinTech, Software, Health Care
Seed, Convertible Note, Initial Coin Offering
United States, Switzerland

Portfolio highlights

ZELF — Zelf is a neobank targeting Gen Z to bring financial services to where they live – in messengers. This is the lightest bank with the easiest onboarding process taking up to 60 sec to issue a card, receive and send money without leaving the messenger. We are uniquely offering AI-powered voice control over the most of financial operations, whichmakes us first voice-enabled banking for Gen Z who prefers voice interactions with their devices.
LimeWire — LimeWire develops peer-to-peer software and solutions for the file sharing industry. It offers LimeWire BASIC and LimeWire PRO, the peer-to-peer file sharing applications which connect to the Gnutella network and enables users to search for and download files through other users; and LimeWire Store, a digital media store. Limewire was founded in2000 and is based in New York, New York. The company operates as a subsidiary of Lime Group LLC.
PreComb Therapeutics — functional precision medicine, oncology, cancer, discovery, organoid, predictive, ai, 3DTwin, data mining, therapy guidance, automated, immune oncology, 2curex, xilis, usz, dkfz, nct, switzerland

The EU framework programme for research and innovation

Investment focus

Biotechnology, Health Care, Software
Grant, Seed, Funding Round
Spain, Switzerland, United Kingdom

Portfolio highlights

NovaMea — NovaMea is a cleantech startup that designs and commercializes electrochemical systems for energy storage and conversion.Its purpose is to create technology, services, and products for the storage and conversion of energy using electrochemical processes, as well as to produce, store, sell, and distribute these products and their components.
Perciv AI — Perciv provides artificial intelligence (AI)-based software solutions to unlock the latent possibilities of radars and allow resilient and economical autonomous systems with Lidar-like performance even in severe weather circumstances.
Neuron Soundware — Neuron Soundware uses Artificial Intelligence and Machine Learning in combination with the analysis of sound and other physical parameters.

Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.

Investment focus

Renewable Energy, Biotechnology, Medical Device
Seed, Pre-Seed, Convertible Note
Switzerland

Portfolio highlights

qCella — qCella Impregnate natural fibers with copper and utilize them to create heating mats that outperform commercially available heating wires. When linked to a power source (e.g., a battery), the mats have the right electrical resistance over the entire structure, allowing them to heat uniformly.
DPhi Space — DPhi Space is a startup that specializes in shared satellites for hosted payloads to simplify access to space. The company's flagship product, Clustergate, is a modular platform that aggregates multiple payloads—such as sensors, antennas, or cameras—into a single container, allowing them to share a satellite. This approach reduces costs andcomplexity by optimizing satellite resources. Clustergate offers built-in in-orbit computing, AI processing, and real-time data analytics, enabling businesses to deploy and manage their technology in space without requiring specialized expertise.
CellX Biosolutions — CellX Biosolutions is the Sustainable treatment of chemical waste.

With more than 30 portfolio companies across AI, pet health, ageing medicine and more, LongeVC provides venture capital for the biotech and longevity sectors.

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Funding Round, Series A
United States, Estonia, Hong Kong

Portfolio highlights

Melio — Melio has created a rapid, precise, and comprehensive blood test that identifies 99% of the most common pathogens in hours, rather than days.
Proton Intelligence — Continuous, real-time, and accurate biomarker monitoring to better manage chronic disease and save lives.
Catena Biosciences — Catena Biosciences uses a novel protein conjugation method to bring breakthroughs in biological therapeutics, autoimmune disorders and vaccine development

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Seed, Series B
France, Switzerland, Spain

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Omnidoc — Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.
Raidium — Radiology augmented GPT to tackle the complexity of precision medicine

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.

Investment focus

Health Care, Hardware, Software
Seed, Series A, Funding Round
Switzerland, France

Portfolio highlights

Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Pivotal Life Sciences specializes in providing capital to innovative companies developing therapeutic products to address major unmet medical needs.

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series B, Series C, Series A
United States, China, Canada

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life

Investors by industry

Artificial intelligence